Dashenlin Pharmaceutical Group Co., Ltd.

In its own account, the company says money comes mainly from selling medicine and health products directly to consumers through its own and franchised stores, with a smaller stream from wholesale supply to independent pharmacies and from fees charged to franchisees for goods, management and services.

CompanyGraph reads its growth as coming from multiplying a standard pharmacy format, opened directly, bought, or run by franchisees, across a widening set of provinces. Its own account describes that expansion now shifting from entering new provinces toward deepening its presence in places it already operates, and the record on file shows revenue, gross profit and net income each growing or staying positive across multiple recent years, consistent with a network that has kept adding profitable units rather than absorbing loss-making ones.

In its own account, the company depends on a large, diversified base of pharmaceutical and health-product manufacturers for what it sells, rather than on any single named supplier, and it names the ability to recruit and retain pharmacy, logistics and store talent as a risk to continued expansion.

In its own account, individual consumers and patients buying at its stores depend on it for everyday access to medicine, and a separate layer of franchise partners, smaller pharmacy chains and independent pharmacies depend on it as their supplier; franchise agreements require those partners to buy exclusively through the company rather than sourcing elsewhere.

On file, a modest number of other companies run this same kind of store-replication business, so it is not a rare way to operate. Several of its profitability measures, including return on assets, operating margin, gross margin and return on equity, sit at the higher end of the peer range across multiple recent years, which describes a comparative financial position rather than a specific mechanism. The company attributes this to its store network scale, integrated supply chain and self-run logistics in its own account, but that is its own stated explanation, and whether competitors could reproduce it is not something the evidence here can show.

For franchise partners specifically, the company's own account describes a contractual requirement to source all merchandise exclusively from the company and to follow its standards for branding, operations, pharmacy service, software and staff training, which structurally ties those stores to the company rather than leaving them free to buy elsewhere. For individual retail customers, the evidence on file shows a large membership program but no contractual barrier to shopping at a different pharmacy.

In its own account, the company names talent availability and retention, regulatory and policy uncertainty, and competitive intensity as what limits its growth, and states that entering a new province requires first building a local store and wholesale base, followed by a lengthy period to establish it, before franchising can follow. CompanyGraph reads this as consistent with a general pattern for store-replication businesses, where growth is limited by each new outlet needing to prove itself before the network extends further, but that general pattern is applied to the industry as a category and is not a measurement made specifically for this company.

The company's own account names intensified competition, industry policy shifts, and its ability to recruit and keep staff as the risks it lists first, and states that none of these had a significant effect on its recent operations. It also discloses a small amount of its bank deposits frozen due to litigation, without describing that litigation as material.

In its own account, the company describes operating under national pharmaceutical distribution standards and medical-insurance program rules, overseen by China's market regulation, healthcare security, traditional medicine and medical products authorities, plus securities regulation as a company listed on the Shanghai Stock Exchange. It names intensifying competition, pharmaceutical and healthcare policy change, and the availability of qualified staff as the outside pressures it lists first.